MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from term loan
and notes payable
$10,000K
Proceeds from the
issuance of common stock
$7,320K
Proceeds from issuance of
common stock under...
$497K
Net cash, cash
equivalents, and restricted...
$16,417K
Canceled cashflow
$1,400K
Net decrease in
cash, cash...
-$7,257K
Canceled cashflow
$16,417K
Depreciation and
amortization
$5,670K
Share-based compensation
expense
$4,139K
Accounts payable and
other accrued...
$1,859K
Accrued interest,
amortization of debt issuance...
$1,304K
Change in fair value of
warrant liability, net
$280K
Provision for credit
losses
$180K
Deferred revenue
$174K
Impairment loss on
intangible assets
$107K
Inventory excess and
obsolescence
$49K
Other
-$817K
Equity financing costs
$532K
Payment of debt issuance
costs
$30K
Repayment of term loan and
notes payable
$21K
Net cash, cash
equivalents, and restricted...
-$23,271K
Canceled cashflow
$13,762K
Net cash, cash
equivalents, and restricted...
-$403K
Revenues
$88,499K
Net loss
-$35,265K
Canceled cashflow
$88,499K
Current and long-term
operating lease...
-$789K
Accounts receivable
$531K
Other current assets
$258K
Other long-term
assets
$121K
Accretion of lease
right-of-use assets
-$69K
Purchase of property and
equipment
$259K
Patent costs and
intangible asset...
$144K
Employee related
expenses (less...
$66,824K
Direct costs and
expenses (less employee...
$12,072K
Interest expense
$7,716K
Sales and marketing
education and event...
$7,562K
Contracted services
expenses
$7,012K
Other segment items
$6,682K
Depreciation and
amortization expense
$5,670K
Share-based compensation
expenses
$4,139K
Occupancy and equipment
service expenses
$4,077K
Clinical trials and
associated costs
$1,730K
Change in fair value of
warrant liability, net
$280K
Back
Back
Cash Flow
source: myfinsight.com
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)